MedTrace Logo

Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation

NCT04737785 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 252

Last updated 2024-08-27

No results posted yet for this study

Summary

All patients undergoing allogeneic or autologous HSCT at the participating centres will be observed. Once a diagnosis of CNS disorder is made, additional data will be reported for these patients.

We will identify clinical and diagnostic characteristics such as cerebrospinal fluid (CSF) and neuroimaging patterns, risk factors, response to treatment (including novel antifungal agents such as isavuconazole) and outcome. In addition, risk factors for CNS disorders after allogeneic and autologous HSCT will be analyzed using a prospectively assessed matched control group. In the future, this study might be the basis for an interventional trial (e.g. using a prophylactic approach).

Conditions

  • Central Nervous System Infections
  • Central Nervous System Complication
  • Infectious Disease of Nervous System
  • Blood Disease
  • Blood Cancer
  • Infection

Sponsors & Collaborators

  • European Society for Blood and Marrow Transplantation

    lead NETWORK

Principal Investigators

  • Martin Schmidt-Hieber, Dr · Carl-Thiem-Klinikum, Clinic for Hematology and Oncology, Cottbus, Germany

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-06-30
Completion
2024-08-01

Countries

  • Australia
  • Colombia
  • France
  • Germany
  • Hungary
  • Israel
  • Italy
  • Poland
  • Russia
  • Spain
  • Tunisia
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04737785 on ClinicalTrials.gov